Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL... see more

TSX:MDNA - Post Discussion

Medicenna Therapeutics Corp > Abstract
View:
Post by ENEMENEMYNEMO on Apr 06, 2024 3:52pm

Abstract

Pickin apart the data...remembering it's from November 23 (submission date)

Clinical Benefit rate of 25% in Melanoma Group at 6 months. Wow! 
Total 16/1PR/3SD >6months
Comment by Galaxym31 on Apr 07, 2024 2:30pm
One PR out of 16 is not a WOW to me .
Comment by ENEMENEMYNEMO on Apr 07, 2024 5:05pm
These are dying patients. No further options. Give a guy an extra 6 months to see his grandkid graduate university, or his child born, or make it to his 50th wedding anniversary. What's that worth?? Giving a little hope to people with no future....
Comment by Galaxym31 on Apr 08, 2024 10:07am
why not two treatments ?
Comment by ENEMENEMYNEMO on Apr 09, 2024 5:54pm
Does a Clinical Benefit Rate of 50% make you a happier investor Galaxie?
Comment by Galaxym31 on Apr 09, 2024 7:42pm
4 PR , 3 SD not feeling it I think they had about 160 people in the GBM trial , if the SP  moves up I will unload .
Comment by ENEMENEMYNEMO on Apr 09, 2024 7:59pm
Good luck to ya!
Comment by windymayor1 on Apr 10, 2024 4:56pm
Impressive day on positive news!
Comment by Peladawn on Apr 18, 2024 9:21am
If you want to see truly impressive, take a look at Oncolytics Biotech (ONCY/ONC.to)....they're about to begin recruiting patients for registrational trials which are likely to result in Accelerated Approvals, and very likely a buyout by one of the big pharma giants that they have been colluding with on all of these trials now for the last few years, and have achieved triple the response rates ...more  
Medicenna Therapeutics Corp
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities